Olympus (7733) Stock Overview
Engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
7733 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Olympus Corporation Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | JP¥1,753.00 |
| 52 Week High | JP¥2,168.00 |
| 52 Week Low | JP¥1,302.50 |
| Beta | 0.21 |
| 1 Month Change | 13.79% |
| 3 Month Change | 33.77% |
| 1 Year Change | -8.44% |
| 3 Year Change | -22.09% |
| 5 Year Change | -25.64% |
| Change since IPO | 423.28% |
Recent News & Updates
Narrative Update • Jun 01
7733: Capital Return And BioProtect Deal Will Likely Fail To Justify Premium
Analysts have lifted their fair value estimate for Olympus from ¥1,500 to ¥1,600, citing increased confidence in the new management team's external medtech experience and the recent upgrade of the stock to Buy with a higher Street price target of ¥2,300. What's in the News Olympus agreed to acquire BioProtect Ltd., a medical device company focused on spacing solutions in cancer care, to expand its urology and oncology portfolio and support the corporate focus on patient safety and outcomes (source: company announcement, 26 May 2026).Analysis Article • May 19
Olympus' (TSE:7733) Soft Earnings Don't Show The Whole Picture
The market was pleased with the recent earnings report from Olympus Corporation ( TSE:7733 ), despite the profit...Recent updates
Narrative Update • Jun 01
7733: Capital Return And BioProtect Deal Will Likely Fail To Justify Premium
Analysts have lifted their fair value estimate for Olympus from ¥1,500 to ¥1,600, citing increased confidence in the new management team's external medtech experience and the recent upgrade of the stock to Buy with a higher Street price target of ¥2,300. What's in the News Olympus agreed to acquire BioProtect Ltd., a medical device company focused on spacing solutions in cancer care, to expand its urology and oncology portfolio and support the corporate focus on patient safety and outcomes (source: company announcement, 26 May 2026).Analysis Article • May 19
Olympus' (TSE:7733) Soft Earnings Don't Show The Whole Picture
The market was pleased with the recent earnings report from Olympus Corporation ( TSE:7733 ), despite the profit...
Narrative Update • May 16
7733: Share Repurchases And Higher Dividends Will Support Future Upside Potential
Analysts have adjusted their price target on Olympus from ¥2,300 to approximately ¥2,214, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E assumptions. What's in the News Board meeting on May 12, 2026, focused on a proposed share repurchase using the ToSTNeT-3 off-auction trading system and other items on the agenda (Key Developments).Analysis Article • May 14
Olympus Corporation Just Beat EPS By 21%: Here's What Analysts Think Will Happen Next
Shareholders of Olympus Corporation ( TSE:7733 ) will be pleased this week, given that the stock price is up 18% to...Narrative Update • Apr 28
7733: Dividend And Margin Outlook Will Offset Product And Leadership Uncertainty
Analysts have kept their ¥1,500 price target for Olympus unchanged, citing slightly lower assumed revenue growth, a modestly higher discount rate, and a higher profit margin outlook. Together, these factors support a similar valuation on a somewhat lower future P/E multiple.Narrative Update • Apr 13
7733: Medtech M&A And Imaging Platform Expansion Will Support Future Upside Potential
Analysts have trimmed the Olympus price target from ¥2,400 to ¥2,300, reflecting updated assumptions around slightly softer revenue growth, lower profit margins, and a higher discount rate, partly offset by a higher future P/E multiple. What's in the News Launched the VISERA ELITE III surgical imaging platform in the U.S., a software driven system that combines True 4K and 3D imaging, Narrow Band Imaging technology, Yellow Enhancement, fluorescence guided surgery, and ENDOEYE scopes in a single platform designed to support multiple surgical specialties and existing Olympus equipment (Product related announcement).
Narrative Update • Mar 30
7733: Future Returns Will Reflect Imaging Platform Adoption And Higher Dividend
Analysts have reduced their Olympus price targets by ¥69 to reflect slightly lower fair value estimates, modest adjustments to revenue growth and profit margin assumptions, and a small change to the future P/E multiple. What's in the News Olympus launched the VISERA ELITE III surgical imaging platform in the U.S., a software driven system that supports minimally invasive procedures across multiple specialties with True 4K, 3D imaging, Narrow Band Imaging technology, Yellow Enhancement and Fluorescence Guided Surgery features in one platform (Key Developments).Narrative Update • Mar 16
7733: Future Returns Will Reflect Imaging Platform Rollout And Dividend Increase
Analysts have lowered their fair value estimate for Olympus from ¥2,077.69 to ¥1,888.46. They cite slightly reduced assumptions for revenue growth, profit margins and future P/E, as well as a modestly higher discount rate in their updated models.Narrative Update • Mar 02
7733: Dividend Hike And Leadership Shift Will Balance Product And Earnings Risks
Analysts have trimmed their price target on Olympus from ¥1,750 to ¥1,500, citing updated assumptions that include slightly lower revenue growth, profit margins, and future P/E, along with a modestly higher discount rate. What's in the News Olympus issued new dividend guidance for the year ending March 31, 2026, with a planned dividend of ¥30.00 per share, compared with ¥20.00 per share a year earlier (company guidance).Analysis Article • Feb 17
Olympus Corporation Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Shareholders in Olympus Corporation ( TSE:7733 ) had a terrible week, as shares crashed 21% to JP¥1,563 in the week...Narrative Update • Feb 15
7733: Medtech M&A And Margin Improvement Will Support Future Upside Potential
Analysts have trimmed their price target on Olympus from ¥2,450 to ¥2,400, reflecting slightly different assumptions for growth, margins and future P/E. They still see the shares as supported by improved profit margin expectations.Analysis Article • Feb 13
Olympus (TSE:7733) Is Paying Out A Larger Dividend Than Last Year
Olympus Corporation ( TSE:7733 ) has announced that it will be increasing its dividend from last year's comparable...Narrative Update • Feb 01
7733: Endotherapy Portfolio Expansion And Buybacks Will Support Future Upside Potential
Analysts now place their price target for Olympus at ¥2,450, down from ¥2,587, citing adjusted fair value estimates, a slightly lower profit margin outlook, and a modestly reduced future P/E assumption, partly offset by marginally higher expected revenue growth. What's in the News Olympus plans a board meeting on January 28, 2026 to consider changes to executive officers, pointing to potential shifts in senior leadership (Board Meeting).Analysis Article • Jan 28
Olympus (TSE:7733) Has Announced That It Will Be Increasing Its Dividend To ¥30.00
Olympus Corporation ( TSE:7733 ) will increase its dividend from last year's comparable payment on the 5th of June to...Narrative Update • Jan 18
7733: Personnel Overhaul And Product Issues Will Eventually Pressure Overvalued Shares
Analysts have kept their fair value estimate for Olympus steady at ¥1,750, citing slightly firmer revenue growth and profit margin assumptions, as well as a marginally lower future P/E multiple, as key supports for the updated price target. What's in the News Olympus agreed with W.Analysis Article • Jan 14
Olympus Corporation's (TSE:7733) Price In Tune With Earnings
Olympus Corporation's ( TSE:7733 ) price-to-earnings (or "P/E") ratio of 23.8x might make it look like a strong sell...Narrative Update • Jan 04
7733: Endotherapy Portfolio Expansion And Buybacks Will Support Bullish Outlook
Analysts have reduced their price target for Olympus to reflect a lower fair value estimate of approximately $2,587.45 from about $3,001.00, citing a higher discount rate that more than offsets improved revenue growth and profit margin assumptions, along with a lower future price-to-earnings multiple. What's in the News Olympus secured exclusive global distribution rights for the GORE VIABIL Biliary Endoprosthesis, with U.S. distribution transitioning from ConMed to Olympus effective January 1, 2026.Analysis Article • Dec 30
Calculating The Intrinsic Value Of Olympus Corporation (TSE:7733)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Olympus fair value estimate is JP¥1,777 With JP¥1,985 share...Narrative Update • Dec 17
7733: Rising Profit Outlook Will Mask Looming Personnel Restructuring Risk
Analysts have raised their price target on Olympus from ¥1,660 to ¥1,750, citing expectations for stronger revenue growth, improving profit margins, and a more attractive future valuation multiple as key drivers of the upward revision. What's in the News Olympus to assume exclusive global distribution rights for the GORE VIABIL Biliary Endoprosthesis, with U.S. commercial support transitioning from ConMed to Olympus effective January 1, 2026; this is expected to strengthen its therapeutic endoscopy portfolio (Strategic Alliances) Issued consolidated earnings guidance for the fiscal year ending March 31, 2026, targeting revenue of ¥998 billion, operating profit of ¥136 billion, and profit attributable to owners of parent of ¥94 billion, implying basic EPS of ¥84.56 (Corporate Guidance) Board scheduled to consider a global personnel optimization program at its November 7, 2025 meeting, signaling potential restructuring or cost efficiency measures (Board Meeting) Completed share repurchases totaling 27,630,600 shares, or 2.45 percent of shares, for approximately ¥50 billion under the buyback program announced May 13, 2025, which enhances capital returns to shareholders (Buyback Tranche Update) Initiated voluntary safety actions on select endoscopy-related devices, including a corrective action for the Single Use Ligating Device PolyLoop and a global removal of certain ViziShot 2 FLEX EBUS TBNA needles manufactured before May 12, 2025, following reported adverse events (Product Related Announcements) Valuation Changes Fair Value Estimate risen moderately from ¥1,660 to ¥1,750, reflecting higher expected earnings and a stronger operating outlook.Analysis Article • Dec 08
Olympus (TSE:7733) Will Pay A Larger Dividend Than Last Year At ¥30.00
Olympus Corporation's ( TSE:7733 ) dividend will be increasing from last year's payment of the same period to ¥30.00 on...Narrative Update • Dec 03
7733: Future Performance Will Reflect Personnel Actions Amid Product Safety And Margin Risks
Analysts have nudged their price target for Olympus modestly higher to approximately $2,078 from about $2,070. This reflects slightly stronger projected revenue growth that more than offsets a marginally softer profit margin outlook, as well as a small uptick in the assumed discount rate and future price to earnings multiple.Analysis Article • Nov 24
Olympus' (TSE:7733) Upcoming Dividend Will Be Larger Than Last Year's
Olympus Corporation's ( TSE:7733 ) dividend will be increasing from last year's payment of the same period to ¥30.00 on...Narrative Update • Nov 19
7733: Future Performance Will Reflect Improved Margins Amid Market And Product Challenges
Analysts have raised their price target for Olympus from $1,951.54 to $2,070.00. They cite improved revenue growth expectations and a stronger profit margin outlook as key drivers for the upward revision.Analysis Article • Nov 10
Olympus (TSE:7733) Will Pay A Larger Dividend Than Last Year At ¥30.00
Olympus Corporation ( TSE:7733 ) will increase its dividend from last year's comparable payment on the 5th of June to...Narrative Update • Nov 04
7733: Market Will Weigh Product Recall Against Modest Guidance Revision Risk
Narrative Update: Analyst Price Target for Olympus Adjusted Analysts have slightly reduced their fair value estimate for Olympus, lowering the price target from $1,976.43 to $1,951.54. The change is attributed to updated expectations for discount rates and revenue growth.Narrative Update • Oct 21
Analysts Lower Olympus Valuation Following Product Recall and Earnings Guidance Revision
Narrative Update on Olympus Analysts have adjusted the fair value estimate for Olympus downward by approximately $30, reflecting updated views on key financial assumptions. What's in the News Olympus completed a share buyback of 20,766,200 shares, representing 1.84 percent, for ¥37,034.97 million between July and September 2025 (Key Developments).Analysis Article • Sep 30
Olympus (TSE:7733) Might Have The Makings Of A Multi-Bagger
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...Narrative Update • Sep 18
Reorganization And OLYSENSE Launch Will Improve Efficiency And Market Share
The consensus price target for Olympus has been revised downward, primarily reflecting a modest decrease in both the company’s future P/E ratio and discount rate, resulting in a lower fair value estimate of ¥2006. What's in the News Olympus launched the VISERA S OTV-S500 imaging platform in the U.S., integrating advanced diagnostic features for ENT and urology with enhanced image quality, compatibility, and content management capabilities.Narrative Update • Aug 27
Reorganization And OLYSENSE Launch Will Improve Efficiency And Market Share
The slight reduction in Olympus’s analyst price target reflects modest declines in both consensus revenue growth and net profit margin forecasts. What's in the News Olympus lowered fiscal year 2026 guidance, with revenue expected at ¥998,000 million (previously ¥999,000 million), operating profit at ¥136,000 million (previously ¥150,000 million), and profit attributable to owners of parent at ¥94,000 million (previously ¥105,000 million).Analysis Article • Aug 12
Earnings Miss: Olympus Corporation Missed EPS By 50% And Analysts Are Revising Their Forecasts
TSE:7733 1 Year Share Price vs Fair Value Explore Olympus's Fair Values from the Community and select yours It's...Analysis Article • Jul 25
A Look At The Intrinsic Value Of Olympus Corporation (TSE:7733)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Olympus fair value estimate is JP¥1,925 Current share price of...Analysis Article • Jul 09
Subdued Growth No Barrier To Olympus Corporation's (TSE:7733) Price
When close to half the companies in Japan have price-to-earnings ratios (or "P/E's") below 13x, you may consider...Analysis Article • Jun 17
Olympus (TSE:7733) Seems To Use Debt Quite Sensibly
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
New Narrative • Nov 24
Cloud-Powered Endoscopy Innovation Fuels Revenue Growth In The Medical Devices Industry
Approval of AI endoscopy devices in the U.S. and Europe is expected to drive revenue growth through improved clinical outcomes and procedural efficiency.Shareholder Returns
| 7733 | JP Medical Equipment | JP Market | |
|---|---|---|---|
| 7D | -6.9% | -3.0% | -3.7% |
| 1Y | -8.4% | 15.5% | 37.9% |
Return vs Industry: 7733 underperformed the JP Medical Equipment industry which returned 15.5% over the past year.
Return vs Market: 7733 underperformed the JP Market which returned 37.9% over the past year.
Price Volatility
| 7733 volatility | |
|---|---|
| 7733 Average Weekly Movement | 7.7% |
| Medical Equipment Industry Average Movement | 4.2% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in JP Market | 9.3% |
| 10% least volatile stocks in JP Market | 2.4% |
Stable Share Price: 7733's share price has been volatile over the past 3 months compared to the JP market.
Volatility Over Time: 7733's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of JP stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1919 | 29,297 | Bob White | www.olympus.co.jp |
Olympus Corporation, together with its subsidiaries, engages in the manufacture and sale of medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through two segments, “Gastrointestinal Solutions and Surgical & Interventional Solutions. The company offers gastrointestinal Solutions products offer gastrointestinal endoscopes, gastroenterology devices, and medical services.
Olympus Corporation Fundamentals Summary
| 7733 fundamental statistics | |
|---|---|
| Market cap | JP¥1.92t |
| Earnings (TTM) | JP¥68.17b |
| Revenue (TTM) | JP¥1.01t |
27.3x
P/E Ratio1.8x
P/S RatioIs 7733 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 7733 income statement (TTM) | |
|---|---|
| Revenue | JP¥1.01t |
| Cost of Revenue | JP¥356.59b |
| Gross Profit | JP¥654.09b |
| Other Expenses | JP¥585.92b |
| Earnings | JP¥68.17b |
Last Reported Earnings
Mar 31, 2026
Next Earnings Date
Aug 07, 2026
| Earnings per share (EPS) | 64.18 |
| Gross Margin | 64.72% |
| Net Profit Margin | 6.75% |
| Debt/Equity Ratio | 29.5% |
How did 7733 perform over the long term?
See historical performance and comparisonDividends
1.7%
Current Dividend Yield49%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/11 13:50 |
| End of Day Share Price | 2026/06/11 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2026/03/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Olympus Corporation is covered by 25 analysts. 12 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Warren Lau | Aletheia Analyst Network Limited |
| Masahiro Nakanomyo | Barclays |
| Ritsuo Watanabe | BofA Global Research |